NCT04971473已完成3 期
An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 1
- 主要终点
- the rate of concordant scans
研究概览
简要总结
This is A non-blinded trial. Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects voluntarily sign the informed consent form (ICF).
- •Age 18-75 years old, either male or female.
- •Patients with diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant,.
- •Patients with a total or near-total thyroidectomy within 6 weeks prior to administered.
- •Low iodine diet for 4 weeks prior to randomized.
排除标准
- •Pregnant or breast feeding women.
- •Patients with other malignancies (exception for in situ cervix uterine cancer, baso cellular skin cancer or breast cancer in remission)
- •Subjects who are unsuitable to the trial in combination with other serious diseases, as identified by the investigator.
- •Subjects who have participated in another clinical trial of a new drug or medical instrument within 1 months before screening.
结局指标
主要结局
the rate of concordant scans
时间窗: 48 hours after the radioiodine administration
scan findings in agreement in a given patient using each preparation method
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single-Dose Administration Trial of TLC599 in Osteoarthritis of the KneeOsteoarthritis of the KneeNCT02803307Taiwan Liposome Company40
招募中
不适用
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast CancerBreast CancerNCT06765590Sichuan Huiyu Pharmaceutical Co., Ltd24
已完成
1 期
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.Type 2 Diabetes MellitusNCT06483243Chong Kun Dang Pharmaceutical45
已完成
1 期
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy MalesHealthyNCT05816356EpiDestiny, Inc.10
终止
1 期
The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild AsthmaticsAsthmaNCT00453791GlaxoSmithKline31